Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.

about

Efficacy of levomilnacipran extended release in treating major depressive disorder.

P2860

Q47303967-DB1DBC38-6451-4267-B3CA-A08057BDCF10

P2860

Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.

Item

http://www.wikidata.org/entity/Q47882128

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Measures of suicidality in pha ...... ith major depressive disorder.

@en

Measures of suicidality in pha ...... ith major depressive disorder.

@nl

type

Item

label

Measures of suicidality in pha ...... ith major depressive disorder.

@en

Measures of suicidality in pha ...... ith major depressive disorder.

@nl

prefLabel

Measures of suicidality in pha ...... ith major depressive disorder.

@en

Measures of suicidality in pha ...... ith major depressive disorder.

@nl

P1476

Measures of suicidality in pha ...... ith major depressive disorder.

@en

P2093

Arif Khan

http://www.w3.org/2001/XMLSchema#string

Carl Gommoll

http://www.w3.org/2001/XMLSchema#string

Changzheng Chen

http://www.w3.org/2001/XMLSchema#string

Kenneth Kramer

http://www.w3.org/2001/XMLSchema#string

Michael E Thase

http://www.w3.org/2001/XMLSchema#string

Suresh Durgam

http://www.w3.org/2001/XMLSchema#string

P2860

Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.

Suicide prevention strategies: a systematic review.

Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study

Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

P304

475-483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1092852916000663

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28521846

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.

about

P2860

P2860

Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921